Imaging Surveillance for Survivors of Breast Cancer: Correlation between Cancer Characteristics and Method of Detection.
10.4048/jbc.2017.20.2.192
- Author:
A Jung CHU
1
;
Jung Min CHANG
;
Nariya CHO
;
Woo Kyung MOON
Author Information
1. Department of Radiology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
ErbB-2;
Follow-up studies;
Recurrence
- MeSH:
Breast Neoplasms*;
Breast*;
Disease-Free Survival;
Female;
Follow-Up Studies;
Humans;
Immunohistochemistry;
Lymph Nodes;
Mammography;
Methods*;
Receptor, Epidermal Growth Factor;
Recurrence;
Survivors*;
Thoracic Wall;
Ultrasonography
- From:Journal of Breast Cancer
2017;20(2):192-197
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of our study was to investigate the characteristics of primary and recurrent breast cancers and the correlation between cancer subtypes and detection modes. METHODS: Between 2003 and 2013, 147 cases of recurrent breast cancer in 137 women (mean age, 45.30±10.78 years) were identified via an annual clinical examination using radiological studies among 6,169 patients with a breast cancer history (mean follow-up period, 13.26±1.78 years). Clinical, radiological, and pathological findings including immunohistochemistry findings of primary and recurrent cancers were reviewed. The size of the tumor in primary and recurrent cancers, disease-free survival, methods of surgery, and the recurrence detection modalities were analyzed with respect to the breast cancer subtype. RESULTS: Ipsilateral and contralateral in-breast recurrence occurred in 105, 21 had axillary lymph node recurrence, and 21 had chest wall recurrences. The subtypes of the primary cancers were hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative (HR+HER2−) in 57, HER2 positive (HER2+) in 39, and triple-negative type in 51, and the recurrent cancers in each subtype showed the same type as the primary cancer in 84.3% of cases. In the in-breast recurrent cancers, the HR+HER2− cancers were most frequently detected using ultrasonography (15/43) followed by mammography (MG) (11/43). The HER2+ recurrent cancers were most commonly detected using MG (14/31, 45.2%), whereas triple-negative type recurrent cancers most commonly presented as symptomatic masses (15/31) (p=0.028). CONCLUSION: Most recurrent breast cancers showed the same cancer subtype as the primary tumor, and recurrent breast cancer subtypes correlated with the detection modality. Imaging surveillance of survivors of breast cancer might be more beneficial in cases of HR+HER2− type breast cancer or HER2+ type breast cancer than in cases of triple-negative type breast cancer.
